Program och talare

08:45
Registration

09.00 - 09.10
Frank Hernandez, WCMM LiU Introduction

9.10 - 9.50
Christian Giske, Karolinska Institute
Keynote: When we finally have new antimicrobials, why are we unable to preserve their activity?

9.50 - 10.30
Markus Zeitlinger, Medical University of Vienna
Keynote: Making Healthy Volunteers sick for greater good: A scientific and ethical journey.

10.30 - 11.00
Posters and fika

11:00 - 11:20
Daniel Aili, LiU
Advanced Wound Dressings for the Detection and Treatment of Infections

11:20 - 11:40
Ignacio Mir Sanchis, WCMM Umeå University
Targeting homologous recombinases in bacteria

11:45 - 13:00
Lunch

13:00 - 13:20
Vicente Pelachano, Karolinska Institute
Leveraging mRNA decay to study antimicrobial resistance

13:20 - 13.40
Yasuhiko Ire, LiU
Opportunistic pathogen Pseudomonas aeruginosa growth as suspended aggregates in high viscosity environments

13:40 - 14:00
Frank J. Hernandez, WCMM LiU
Nucleases as biomarkers for personalized therapeutics

14.00 - 14.40
John Rex, Chief Medical Officer, F2G Ltd; Editor-in-Chief, AMR.Solution, Chair, AMR Action Fund SAB; Operating Partner, Advent Life Sciences
Keynote: The importance of (new) antibacterial and antifungal drugs: And why don’t we have the drugs we need?

14.40 - 15.00
Panell discussion: Antimicrobial Apocalypse: Facts and Challenges

15:00 - 16:00
Afternoon fika and posters

16.00 - 16.20
Claudio Cantù, WCMM LiU
Can we map the action of all (all!) the genome regulators?

16:20 - 16:40
Johan Karlsson, LiU
Nanoparticles for Cell Programming to Shape Anti-Tumor Responses

16.40 - 17.00
Dominic Wright, LiU
Winding back the clock - the genome-edited re-wilded chicken

17.00
Closing remarks day 1

18.00
Dinner at Restaurant von Dufva Gränden Duvan 3A, 582 22 Linköping

9.00 - 9.10
Rolf Saager, WCMM LiU Introduction

9:10 - 9:50
Natascha Mesinkovska, University of California, Irvine
Keynote: The Joy of Science: From counting nose hairs to novel medications

9.50 - 10.20
Posters and fika

10.20 – 11.00
Rolf Saager, WCMM LiU & Ahmed Elserafy, LiU
Development and evaluation of cell-based therapies for skin wounds

11.00 - 11.20
Hanna Israelsson Larsen, WCMM associated clinical fellow LiU
The importance of knowing your goal - does missing data = zero results? Implementing primary care behavioral health in Swedish primary care

11.20 - 12.00
Jörg Schilcher WCMM clinical fellow LiU & Anton Wiberg, LiU
3D visualization and printing to improve outcome in complex joint replacement surgery of the hip

12.00 - 13:00
Lunch

13:00 - 13:20
Daniel Wilhelm, WCMM associated clinical fellow LiU
Revealing the face of sickness- how novel imaging methods can help see the microvascular mechanisms of acute illness

13:20 - 13.40
Antonio Lentini, DDLS fellow LiU TBA

13.40 – 14.00
Nicholas Pearce, DDLS fellow LiU TBA

14.00 - 14.20
David Engblom, WCMM Director LiU WCMM at LiU & closing remarks

Director of Clinical Research and Assistant Professor at the University of California, Irvine (UC Irvine), Department of Dermatology. Considered one of the foremost alopecia experts in the United States, Dr. Mesinkovska has grown the UC Irvine Dermatology Clinical Research Center into a world-class facility with multiple pharmaceutical sponsored studies and investigator-initiated projects focusing on elucidating the pathogenesis of alopecia.

Unashamedly Curiosity-Driven, she has developed unconventional investigational methods that has received international recognition as the igNobel Prize winner in Medicine 2023

Chief Medical Officer, F2G Ltd; Editor-in-Chief, AMR.Solution, Chair, AMR Action Fund SAB; Operating Partner, Advent Life Sciences

Prof. Rex is a physician, drug developer, and global advocate for antimicrobial resistance (AMR) policy, with over 35 years of experience. His work spans clinical care, drug development, and the advancement of policies that combat AMR. A pioneer in the field, Dr. Rex has played an integral role in developing new antibacterial treatments and innovative regulatory pathways. He is also Chair of the Scientific Advisory Board for the $1 billion AMR Action Fund, a key initiative supporting late-stage antimicrobial development. His career reflects a tireless commitment to global health, from academic roles to industry leadership, working across the globe to shape the future of antimicrobial therapy.

The importance of (new) antibacterial and antifungal drugs: And why don’t we have the drugs we need?

Markus is a specialist in Internal Medicine and Clinical Pharmacology and has advanced to his current position as Head of the Department of Clinical Pharmacology. In 2007, he received his post-graduate diploma in Clinical Research. Beside clinical trial design his scientific interests cover antimicrobial agents with focus on early phases of clinical research. He has published over 300 peer reviewed publications and as scientific expert to the European Medicines Agency (EMA) he was actively involved in more than 450 scientific advice procedures given by the agency.

Making Healthy Volunteers sick for greater good, Phase 1 studies on human that do not require medical intervention is a polarizing subject. However, “Medical progress is based on research that ultimately must include studies involving human subjects.” (Declaration of Helsinki, WMA). A scientific and ethical journey.

Professor and Head of Division of Clinical Microbiology, Karolinska Institutet and Chief consultant physician in bacteriology, Karolinska University Hospital. Christian is the head of a translational research group at Karolinska Institutet working with various aspects of antimicrobial resistance. The projects are related to 1) mechanisms of resistance to novel antimicrobials; 2) microbiome impacts of antimicrobials, and 3) novel therapies - in particular bacteriophage therapy. Giske is the past chair of the European Committee on Antimicrobial Susceptibility Testing and is an advisor for the European Centres for Disease Control and Prevention and for Clinical and Laboratory Standards Institute. He is also in the Scientific Advisory Board of Joint Programming Initiative on Antimicrobial Resistance.

When we finally have new antimicrobials, why are we unable to preserve their activity? A key challenge for new drugs is the quick rise of resistance, especially in antimicrobials, limiting their lasting impact.